PALOMA-3: Clinical Implications

Panelists discuss how PALOMA-3’s findings have significantly impacted clinical practice by establishing palbociclib plus fulvestrant as a standard treatment option for patients with hormone receptor–positive, HER2-negative advanced breast cancer who have progressed on prior endocrine therapy.

EP: 1.EGFR mNSCLC Front-Line: Treatment Options

EP: 2.EGFR mNSCLC: Challenges with Treatments in this Space

EP: 3.EGFR mNSCLC Front-Line Treatment Options: Challenges and AEs

EP: 4.PALOMA-3: Study Design and Baseline Characteristics

EP: 5.PALOMA-3: Key End Points: Pharmacokinetic and Secondary

EP: 6.PALOMA-3: Key Safety Data

EP: 7.PALOMA-3: Managing AEs

Now Viewing

EP: 8.PALOMA-3: Clinical Implications

Recent Videos